Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1708 | Helmet non-invasive ventilation (NIV) Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients. A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work from our and other groups suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. In this randomized double blinded case-control trial, the investigators will treat elderly (>70 year old) COVID19 patients with 1 g of nicotinamide riboside (NR-E) or placebo for 2 weeks and investigate if this affects the clinical course of the disease.
Description: Hypoxic respiratory failure as defined by need for oxygen therapy
Measure: Hypoxic respiratory failure Time: Day 1Description: Hypoxic respiratory failure as defined by need for oxygen therapy
Measure: Hypoxic respiratory failure Time: Day 7Description: Hypoxic respiratory failure as defined by need for oxygen therapy
Measure: Hypoxic respiratory failure Time: Day 14Description: Hypoxic respiratory failure as defined by need for oxygen therapy
Measure: Hypoxic respiratory failure Time: Day 90Description: Overall mortality
Measure: Mortality Time: Day 1Description: Overall mortality
Measure: Mortality Time: Day 7Description: Overall mortality
Measure: Mortality Time: Day 14Description: Overall mortality
Measure: Mortality Time: Day 90Description: Sepsis
Measure: Sepsis Time: Day 1Description: Sepsis
Measure: Sepsis Time: Day 7Description: Sepsis
Measure: Sepsis Time: Day 14Description: Sepsis
Measure: Sepsis Time: Day 90Description: Circulatory failure as defined by a need for interventions to support the circulatory system.
Measure: Circulatory failure Time: Day 1Description: Circulatory failure as defined by a need for interventions to support the circulatory system.
Measure: Circulatory failure Time: Day 7Description: Circulatory failure as defined by a need for interventions to support the circulatory system.
Measure: Circulatory failure Time: Day 14Description: Circulatory failure as defined by a need for interventions to support the circulatory system.
Measure: Circulatory failure Time: Day 90Description: Days in hospital
Measure: Days in hospital Time: Day 1Description: Days in hospital
Measure: Days in hospital Time: Day 7Description: Days in hospital
Measure: Days in hospital Time: Day 14Description: Days in hospital
Measure: Days in hospital Time: Day 90Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.
Measure: NAD levels Time: Day 1Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.
Measure: NAD levels Time: Day 7Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.
Measure: NAD levels Time: Day 14Description: Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.
Measure: NAD levels Time: Day 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports